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ABSTRACT 
Enzymes are important not only for the growth and multiplication of the microorganism but also in the infection, penetration of the host tissue 
and encountering host defense mechanisms. This study aims to investigate extracellular protease and DNase activity in clinical (20) and 120 
environmental isolates of C. neoformans species complex collected from different localities of central India.  DNase test agar containing toluidine 
blue and Yeast Carbon Base (YCB) agar medium supplemented with 0.1% BSA + 0.01% polypeptone was employed for the screening of DNase 
and protease production respectively. DNase and protease production was detected by the appearance of clear zones around the colonies. On 
the basis of enzymatic activity and their Pz values, high protease production (Pz≤0.6) was observed by 14 (11.6 %) environmental and 4 (11.6 
%) clinical strains on 5th day, whereas 35 (29.16 %) environmental and 8 (40 %) clinical strains were screened on 8th day of incubation. 
Similarly 13 (10.83%) environmental and 3 (15 %) clinical strains on the 5th day, however 32 (26.66%) environmental and 8 (40 %) clinical 
strains on the 8th day of incubation were found to be high DNase producing strains with low Pz value (Pz≤0.6). In the case of protease activity, 
no significant difference was observed whereas a significant difference has shown by clinical C. neoformans and C. gattii strains on the 5th day of 
DNase production (p < .001). Extracellular enzymes play a vital role in the pathogenicity and virulence of C. neoformans species complex, 
therefore, enzymes are considered as worthy targets for developing therapeutics. 
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INTRODUCTION: 
Opportunistic pathogens Cryptococcus neoformans and 
Cryptococcus gattii are the members of Cryptococcus 
neoformans species complex1. C. neoformans has been 
classified into two varieties and three serotypes i.e. serotype 
A for Cryptococcus. neoformans var. grubii, serotype D for C. 
neoformans var. neoformans and serotype AD for the hybrids 
of serotype A and D. C. gattii was previously known as C. 
neoformans var. gattii but currently it is considered as 
phylogenetically related but distinct species and contains 
serotype B and C2-5. 
Cryptococcus neoformans and Cryptococcus gattii both 
species were reported for the production of a panoply of 
extracellular enzymes6 like proteases 7, urease 8-9, 
phenoloxidase, phospholipases10 and DNase11. 
C. neoformans infection commonly acquires from the 
environment 12, the mechanism includes tissue invasion and 
is disseminated to other organs via the bloodstream from 
the lung 13-15. Studies of experimental infection in rats 
suggested C. neoformans produces tissue disrupting 
substances such as proteolytic enzymes through which it can 
penetrate the lung parenchyma and histopathological 
studies suggested in-vivo protease production which 
degrades collagen fibrils in infected tissues 16. 
Cryptococcal proteases have been associated with the 
virulence and are responsible for the destroying host tissues 
and for digesting several important host proteins such as 
collagen, elastin, fibrin, fibrinogen, immunoglobulins and 
complement factors 17, 7, 10. 
MATERIAL AND METHODS: 
Clinical and environmental isolates: 
In the present investigation, environmental and clinical 
samples were collected from various sources. Environmental 
sources include decaying woody debris inside the living tree 
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trunk hollows, fruits, flowers of various plant species, soil, 
vegetables and desiccated excreta of a few species of caged 
birds, were collected from different localities of central 
India18. Clinical samples (blood, urine, CSF) of cancer 
patients were collected from Netaji Subhash Chandra Bose 
Medical College and Civil Hospital, Jabalpur City (Madhya 
Pradesh).  
Determination of protease production: 
Determination of protease production was performed in 
which all the isolates were evaluated for their ability to 
secrete protease on solid medium containing Bovine serum 
albumin (BSA) 19. 
Yeast carbon base (YCB) agar medium containing 11.7% YCB 
(Himedia Mumbai) supplemented with 0.1% BSA plus 0.01% 
polypeptone, pH was adjusted to 5, sterilized by filtration 
through a membrane filter of 0.2µm pore size. To prepare 
200 ml of medium, 20 ml of the YCB solution will be added 
to 160 ml of 1.88% melted agar at 56˚C and then 20 ml of the 
BSA solution will be added to the medium. Twenty ml 
portions of the media thus prepared were poured into Petri 
dishes and media were referred to as YCB-BSA. Test isolates 
were grown on Sabouraud dextrose agar (SDA) for 24hr for 
28˚C. Then each isolate was spot inoculated in triplicates and 
incubated at 37˚C for 5 days. Then the plates were fixed with 
10% trichloroacetic acid (TCA) for 2hr and then stained with 
Coomassie Brilliant Blue G-250. Protease production was 
detected by the appearance of proteolytic zones around the 
colonies. Reference strain C. albicans MTCC 227/ATCC 
10231 served as positive control and strain of C. glabrata 
IHEM 22129 served as negative control. 
Determination of DNase production: 
The method used for detecting extracellular DNase 
production by C.neoformans sp. The complex was similar to 
the procedure used for detecting DNase production by 
Staphylococci. Plates of DNase Test Agar (Difco) 
supplemented with toluidine blue were prepared. Then each 
isolate was spot inoculated in triplicates and incubated at 
30˚C for 7 days. Then the inoculated plates were flooded 
with 1 N hydrochloric acid. Yeasts that depolymerized DNA 
contained in the medium exhibited clear zones surrounding 
the colonies, whereas those organisms which exhibited no 
extracellular DNase activity showed only the opaque 
background of precipitated DNA 20, 11. 
Measurement and calculation of Pz value 
Protease and DNase activity was measured in terms of a 
ratio of the diameter of the colony to the total diameter of 
the colony plus zone of precipitation. Scoring was done 
according to the method described previously21. According 
to different Pz values strains were categorized into 5 
different categories: -ve (Pz =1) very high Pz group 
(Negative for enzyme production), +/- (Pz = 0.90-0.99) high 
Pz group, ++ (Pz = 0.80-0.89) Intermediate, +++ (Pz = 0.70-
0.79) low Pz group, ++++ (Pz ≤ 0.69) very low Pz group 
(large amount of enzyme production).The strains exhibiting 
(-) and (+) Pz groups were considered negative in the study. 
Statistical analysis: 
The data analysis was performed using SPSS statistics of 
independent ‘t’ test and the critical levels of significance of 
the results were considered at 0.05 levels i.e. P<0.001 was 
considered significant for DNase activity. 
RESULT AND DISCUSSION:  
The present study was focused on the determination of 
DNase and protease activity on the clinical and 
environmental strains of Cryptococcus neoformans and 
Cryptococcus gattii. On the basis of enzymatic activity and 
their Pz values, clinical and environmental strains has been 
divided into five ranges, class and Pz groups. Results are 
shown in (Table 1 & 2).  
 
 
Table 1. Scoring of Protease and DNase producing environmental isolates of Cryptococcus neoformans species complex 
into 5 different categories according to their different Pz values calculated on the 5th and 8th day of incubation. 
 
Table 2.  Scoring of Protease and DNase producing clinical isolates of Cryptococcus neoformans species complex into 5 
different categories according to their different Pz values calculated on the 5th and 8th day of incubation. 
 
Table 3 shows statistical results of enzymatic activity on 85 C. neoformans and 35 C. gattii isolates of environmental origin, 18 C. 
neoformans and 35 C. gattii isolates from clinical samples of a cancer patient using SPSS software.  
Range Class Pz Group Production Frequency of Environmental  isolates  
5th day  8th day  
Protease DNase Protease DNase 
Pz=1 - Very high No production 21 (17.5 %) 23 (19.16 %) 10 (8.33 %) 11 (9.16%) 
Pz= 0.9. – 0.99 +/- High Very low 28 (23.3 %) 37 (30.83 %) 11 (9.16 %) 16 (13.33 %) 
Pz= 0.8. – 0.89 ++ Intermediate Low 27 (22.5 %) 28 (23.3 %) 26 (21.66 %) 27 (22.5 %) 
Pz= 0.70 – 0.79 +++ Low High        30 (25%) 19 (15.8 %) 38 (31.66 %) 34 (28.33 %) 
Pz= ≤0.69 ++++ Very low Very high 14 (11.6 %) 13 (10.83%) 35 (29.16 %) 32 (26.66%) 
Range Class Pz Group Production Frequency of Clinical Isolates 
5th day  5th day  
Protease DNase Protease DNase 
Pz=1 - Very high No production 3 (15 %) 3 (15 %) 1 (5 %) 2 (10 %) 
Pz= 0.9. – 0.99 +/- High Very low 3 (15 %) 5 (25 %) 1 (5 %) 2 (10 %) 
Pz= 0.8. – 0.89 ++ Intermediate Low 7 (35 %) 3 (15 %) 3 (15 %) 5 (25 %) 
Pz= 0.70 – 0.79 +++ Low High    3 (15 %)          6 (30%) 7 (35 %) 3 (15 %) 
Pz= ≤0.69 ++++ Very low Very high 4 (11.6 %) 3 (15 %) 8 (40 %) 8 (40 %) 
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Table 3. Test of Significance in Proteinase and DNase activities of environmental & clinical C. neoformans and C. gattii 
isolates at 5 and 8 days of incubation using independent‘t' test. 
Strain and types Number of 
isolates 
Days of 
incubation 
Enzymes 
tested 
Positive 
Production (%age) 
Significance 
Environmental 
C. neoformans 
C. gattii 
 
85/120 
35/120 
 
5-days 
 
 
 
Protease 
 
99/120 (82.5 %) 
 
NS 
8-days 110/120 (91.66 %) NS 
Clinical 
C. neoformans 
C. gattii 
 
18/20 
2/20 
 
5-days 
 
17/20 (85 %) 
 
NS 
8-days 19/20 (95 %) NS 
Environmental 
C. neoformans 
C. gattii 
 
85/120 
35/120 
 
5-days 
 
 
   
DNase 
 
97/120 (80.33 %) 
 
NS 
8-days 109/120 (90.83 %) NS 
Clinical 
C. neoformans 
C. gattii 
 
18/20 
2/20 
 
5-days 
 
20/20 (100 %) 
 
S (p<0.001) 
8-days 18/20 (90 %) NS 
NS (nonsignificant), S (significant, p<0.001) 
Protease and DNase activity by the formation of clear zones around the Cryptococcus colonies were observed on the 5th and 8th 
day of incubation.  
Figure 1 Protease activity seen by the formation of proteolytic zones around the Cryptococcus colonies with low Pz 
group (Pz=0.48). 
5th day  8th day  
 
Figure 2. screening results for DNase production by the formation of clear zones around the Cryptococcus colonies on 
the 5th and 8th day of incubation with low Pz group (Pz=0.51)  
5
th
 day 8th day  
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An evaluation of protease activity was done by determining 
the Pz values of all the environmental and clinical strains. 
High Pz values (Pz =1) were observed by B1, B3, C-1, T27, 
T32, T 42, T45, T44, T46, T57, T61, T65, T69, T74, P9, P12, 
P19, P20, and P25. High protease production was exhibited 
by strains with isolate number: C-10 (C. neoformans var. 
grubii), isolated from a bone cancer patient. C-13 (C. 
neoformans var. grubii), isolated from a blood cancer patient, 
C-20 (C. neoformans var. grubii), isolated from ovarian 
cancer patient T-13 (C. gattii) isolated from living tree 
hollow of Terminalia. arjuna, T-38 (C. gattii), isolated from 
living tree hollow of Ficus religiosa and  P-24 (C. neoformans. 
var. neoformans), isolated from pigeon excreta. Result was 
shown in Graph 3 and 4. 
An evaluation of DNase activity was done by determining the 
Pz values of all the environmental and clinical strains. 
Highest Pz values (Pz =1) on 5th day were observed by the 
C1, C6, C1, P6, P16, P18, P31, F1, T2, T13, T19, T23, B2, B3, 
T26, T41, T42, T47, B6, T63, T64, T68, T70. However high 
DNase production was obtained by strain C-8 (C. neoformans 
var. grubii), isolated from a lung cancer patient. C-14 (C. 
neoformans var. grubii), isolated from breast cancer patient, 
C-17 (C. neoformans var. grubii), isolated from breast cancer 
patient T32- (C. gattii) isolated from living tree hollow of 
Peltophorum dulce, T-35 (C. gattii), isolated from living tree 
hollow of Ficus religiosa, and P-24 (C. neoformans var. 
neoformans), isolated from pigeon excreta. 
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In this study we examined protease activity of  C. neoformans 
and C. gattii of clinical and environmental origin by following 
the method 19, in which extracellular protease activity was 
examined on 8 clinical (AIDS patients) strains of C. 
neoformans by solid and liquid YCB media supplemented 
with BSA and polypeptone, which is required as a carbon 
and nitrogen source, required for efficient and rapid growth 
in the early stages of development and important for the 
later efficient production of protease activity. 
Identification and discrimination between clinical and 
environmental isolates of C. neoformans varieties can be 
done on the basis of extracellular enzyme activities 22. 
However, we did not find any difference in the enzyme 
activities by clinical and environmental isolates of C. 
neoformans. 
Our results support study who reported that both species 
produce extracellular DNase, but clinical isolates of C. 
neoformans produce significantly more extracellular DNase 
than environmental isolates 20. Extracellular DNase activity 
exhibits an essential role of in the taxonomic and 
phylogenetic studies of the genus Cryptococcus 11. 
In the present investigation, DNase activity was evaluated by 
clinical and environmental strains of Cryptococcus species. 
DNase activity is responsible for the elevation of the innate 
immune system in group A Streptococcus infection23. 
Similarly, in cryptococcal infection, neutrophils provoke an 
inflammatory response and found in close association with 
the infected tissue24-25.  
In the present findings, a statistically no significant 
Difference was observed in the environmental and clinical 
isolates C. neoformans species complex positive for protease 
activity using independent ‘t’ test (p<0.001). Whereas a 
significant difference was observed in the clinical strains on 
the 5th day of DNase production. 
CONCLUSION: 
Analysis of the results obtained suggests that the capacity of 
Cryptococcus neoformans species Complex to produce 
protease and DNase may contribute to fungal virulence 
associated with cryptococcosis. This finding opens a new 
gateway for the research of new therapeutic strategies 
associated with these target virulence factors. 
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